We have sequentially investigated the expression of natural killer cell inhibitory receptors (KIRs) for HLA-C (CD158b) on peripheral blood mononuclear cells (PBMC) in three patients with extensive chronic graftversus-host disease (cGVHD) after allogeneic bone marrow transplantation (alloBMT). Clinical symptoms of cGVHD were not cured and worsened in the first patient whose CD158b-positive cells increased to 18.5% during cGVHD and decreased to 9.4% at 8 months after transplantation. On the other hand, cGVHD was cured and did not relapse in the second patient whose CD158b-positive cells increased up to 45.9% during cGVHD and sustained 19.4% at 8 months after transplantation. In contrast, CD158b-positive cells were less than 10% during the course of cGVHD in the third patient, and her cGVHD did not respond to treatment. Therefore, it appears that chronic allostimulation augments the expansion of CD158b-positive cells and these expanded CD158b-positive cells may have some role in the control of alloresponse in some patients. Bone Marrow Transplantation (2000) 26, 287-290.
Killer cell inhibitory receptors (KIRs) on NK cells negatively regulate NK functions including target cell lysis through their binding to MHC class I molecules. 1 The HLA-C alleles recognized by CD158a share the Asn77 and Lys80 (group 1 HLA-C; Cw2, 4, 5, 6) whereas the HLA-C alleles recognized by CD158b share the Ser77 and Asn80 (group 2 HLA-C; Cw1, 3, 7, 8) . 2 KIRs on T cells can also down-regulate T cell killing function. NK-like activity and anti-TCR-induced killing activity of CTL expressing KIR was suppressed by the stimulation of KIR. 3 Therefore, KIR expression on T cells has an important role in the regulation of killing activity of T cells. 4 However, it is not clear whether KIR on T cells regulates T cell killing function in allogeneic stimulation. Also, the expression of KIR on NK cells and T cells after allogeneic BMT has not been studied. In the present study, we have investigated the expression of CD158b on PBMC in patients with extensive cGVHD after allogeneic BMT.
Case reports

Case 1
A 32-year-old man with severe aplastic anemia underwent HLA-A, B, C (group 2), DR serologically matched related bone marrow transplantation. The conditioning regimens used were cyclophosphamide (50 mg/kg for 4 days), antilymphocyte globulin (ALG, 30 mg/kg for 5 days) and total lymphoid irradiation (TLI, 7.5 Gy). The patient was given cyclosporin A (3 mg/kg) and methotrexate (15 mg/m 2 for 1 day and 10 mg/m 2 for 2 days) as prophylaxis for GVHD. Neutrophil engraftment was obtained on day 20. He did not develop acute GVHD. However, G-CSF-mobilized peripheral blood stem cell transplantation (PBSCT), without preparative treatment, on day 95 after first alloBMT from the same donor, was performed because of platelet recovery failure even after methylpredonisolone pulse therapy. His platelet count increased to 50 × 10 9 /l 14 days after the first allogeneic PBSCT. He developed extensive cGVHD with skin, oral eruption and liver dysfunction 2 months after alloPBSCT (5 months after first alloBMT). Surface molecules on PBMC were identified by dual-color flow cytometry (FACS Calibur; Becton Dickinson, San Jose, CA, USA). Approximately 2 × 10 5 cells suspended in 50 l of Hank's buffer with 1% BSA were incubated with 2.5 l of PE-conjugated anti-KIR mAb and FITC-conjugated anti-T cell mAb for 20 min at 4°C. The phycoerythrin (PE)-conjugated monoclonal antibody (mAb) GL183 (p58.2, CD158b) was purchased from Immunotech (Marseille, France). FITC-conjugated anti-CD3 and anti-CD8 mAb were purchased from Pharmingen (San Diego, CA, USA elevated proportion of CD158b + /CD3 + (CD158b + /CD8 + ) cells then gradually decreased to 2.8% (2.8%) accompanied by relief of clinical symptoms of cGVHD. However, his cGVHD was not cured but worsened again 9 months after first alloBMT. The CD158b + /CD3 − cell level was low (less than 10%) both at 2 months and 8 months after the first BMT. The highest proportion of CD158b-positive cells was 18.5% during cGVHD and decreased to 9.4% 8 months after transplantation (Figure 1a) .
Case 2
A 22-year-old woman with myelodysplastic syndrome (refractory anemia) underwent alloBMT from an HLA-A, B, C (group 2), DR serologically matched unrelated donor. The conditioning regimens used were cyclophosphamide (60 mg/kg for 2 days), Ara-C (2 g/m 2 for 2 days), antithymocyte globulin (ATG, 15 mg/kg for 5 days) plus total lymphoid irradiation (TLI, 7.5 Gy). She was given cyclosporin A (3 mg/kg) and methotrexate (15 mg/m 2 for 1 day and 10 mg/m 2 for 2 days) as prophylaxis for GVHD. She did not develop aGVHD, however, she developed extensive cGVHD with skin eruption following diarrhea with abdominal pain 3 months after alloBMT. Skin eruption and diarrhea responded to and were diminished by the administration of prednisolone and FK506. The proportion of CD158b + /CD3 + (CD158b + /CD8 + ) cells increased to 31.2% (31.5%) on day 137 after the relief of cGVHD by the appropriate treatment. This elevated proportion of CD158b + /CD3 + (CD158b + /CD8 + ) cells remained at this higher level (more than 5%) until 9 months after transplantation without disease relapse and cGVHD never developed again in this patient even though the administration of immunosuppresive drugs was discontinued 7 months after alloBMT. The CD158b + /CD3 − cell level was higher (more than 10%) than in case 1 both 2 months and 8 months after BMT. The highest proportion of CD158b-positive cells was 45.9% during cGVHD and was sustained at 19.4% 8 months after transplantation (Figure 1b) .
Case 3
A 25-year-old woman with chronic myelogenous leukemia (CML) underwent alloBMT from an HLA-A, B, C (group 2), DR serologically matched related donor. The conditioning regimens used were cyclophosphamide (60 mg/kg for 2 days) and total body irradiation (TBI,12 Gy). She was given cyclosporin A (3 mg/kg) and methotrexate (15 mg/m 2 for 1 day and 10 mg/m 2 for 2 days) as prophylaxis for GVHD. She did not develop aGVHD but developed extensive cGVHD with oral eruption and severe liver dysfunction 3 months after alloBMT. Her liver dysfunction did not respond to the administration of prednisolone and FK506. The expression of CD158b on CD3 + and CD8 + cells was very low during cGVHD. Also, the CD158b + /CD3 − cell level was less than 10%. The highest proportion of CD158b-positive cells was also less than 10% after transplantation. She died with fungal pneumonia 9 months after BMT (Figure 1c ).
Discussion
The interaction between KIRs expressed on NK cells and MHC molecules expressed on target cells leads to the inhibition of NK cell function. Also, the effect of KIRs on T cells appears to be to inhibit stimulatory signals mediated by TCR ligation. 5 Partially HLA-matched BMT produced a large expansion of donor-derived CTLs expressing CD158b KIR which inhibit GVHD but allow a discriminatory GVL reaction. 6 The transgenic expression of CD158b KIR pre-
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vents the in vivo rejection of H-2-mismatched mice bone marrow graft. 7 GVL effector and engraftment facilitating mechanism which is independent of T cell-mediated GVH reaction may be operational in HLA-mismatched hematopoietic cell transplantation based on the rule of KIR incompatibility. 8 Also, it has been reported that mixed lymphocyte reaction and anti-CD3 monoclonal antibodyredirected cytotoxicity could be inhibited by engagement of transgenic CD158b molecules in CD158b transgenic mice. 9 However, the expression of KIR on NK cells and T cells after human alloBMT is not well known. We showed that CD158b + /CD3 − cells, mainly NK cells, increased early after alloBMT (Ͻ2 months) and were sustained but gradually decreased for more than 6 months. In contrast, CD158b expression on CD3 + T cells was increased from 3 months after alloBMT. Furthermore, the percentage of both CD158b + /CD3 + cells and CD158b + /CD8 + cells was significantly increased in patients with cGVHD compared with patients without cGVHD. 10 There is a correlation between the increased expression of CD158b on PBMC and clinical improvement of cGVHD in our patients. Clinical symptoms of cGVHD were cured and did not relapse in case 2 whose CD158b-positive cells increased to 45.9% (CD158b + /CD3 + cells were 31.2%) during cGVHD and were sustained at 19.4% (CD158b + /CD3 + cells were 7.0%) 8 months after transplantation. On the other hand, clinical symptoms of cGVHD were not cured and worsened again in case 1 whose CD158b-positive cells were increased to 18.5% (CD158b + /CD3 + cells were 12.3%) during cGVHD but decreased to 9.4% (CD158b + /CD3 + cells were 2.8%) 8 months after transplantation. Also, CD158b-positive cells did not increase in case 3 who developed uncontrollable extensive cGVHD. Therefore, chronic allostimulation during cGVHD augments the expansion of CD158b-positive cells, especially CD158b + /CD8 + cells, and these expanded CD158b-positive cells may have some role in suppressing alloresponse in some patients. Although KIR effect on T cells varies upon cell activation stage, it is an interesting hypothesis that KIR expression on T cells allows the cells to down-regulate an immune response and has some role in induction of peripheral tolerance.
